PureTech Health is a biotherapeutics company engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. Co.'s wholly owned pipeline includes therapeutic candidates, such as LYT-100, a clinical therapeutic candidate that it is pursuing for the treatment of a range of conditions involving inflammation and fibrosis and disorders of lymphatic flow; and LYT-200, a clinical immuno-oncology fully human monoclonal antibody candidate targeting a foundational immunosuppressive protein. We show 1 historical shares outstanding datapoints in our coverage of PRTC's shares outstanding history.
Understanding the changing numbers of PRTC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PRTC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PRTC by allowing them to research PRTC shares outstanding history
as well as any other stock in our coverage universe. |
Free PRTC Email Alerts:
Video: Shares Outstanding Importance
